QR код

Niraparib PBPK modeling to predict optimal dosage in patients with hepatic impairment

ObjectiveTo develop a physiologically based pharmacokinetic (PBPK) model of niraparib, predictive of optimal dosage in patients with hepatic impairment and of key pharmacological factors of toxicity.MethodsA comprehensive systematic literature review was conducted in PubMed and ClinicalTrials.gov, t...

Повний опис

Збережено в:
Автори: Anatoly Pokladyuk, Veronika Voronova, Gabriel Helmlinger, Kirill Peskov, Yuri Kosinsky
Формат: Artigo
Мова:Inglês
Опубліковано: Frontiers Media S.A. 2026-05-01
Серія:Frontiers in Pharmacology
Предмети:
ABC-SMC
hepatic impairment
niraparib
PARP inhibitors
PBPK modeling
Онлайн доступ:https://www.frontiersin.org/articles/10.3389/fphar.2026.1736762/full
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси